Caroline Robert scientifique française
Robert, Caroline 1973-....
Robert, Caroline, 1973-...., médecin
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Robert, Caroline.
VIAF ID: 78798245 (Personal)
Permalink: http://viaf.org/viaf/78798245
Preferred Forms
4xx's: Alternate Name Forms (4)
Works
| Title | Sources |
|---|---|
| Clinical peculiarities and therapeutic impact of immune-related adverse events in patients with stage ΙV melanoma. |
|
| Dermatología de los tratamientos contra el cáncer guía práctica |
|
| Dermatologie des traitements anticancéreux guide pratique |
|
| Dermatology and anticancer therapies practical handbook |
|
| Frôlements et roulements: interactions des cellules dendritiques avec les endothélium : implication en immunothérapie |
|
| Influence de l'alimentation de la parturiente sur la progression du travail |
|
| Inhibiteurs de BRAF dans le traitement du cancer : Contribution à l'étude des mécanismes de résistance et des effets secondaires paradoxaux |
|
| Maîtriser les effets cutanés de son traitement anti-EGFR |
|
| nouvelle dermatologie manifestations cutanées des thérapies ciblées anticancéreuses |
|
| ombre au soleil le mélanome |
|
| [Physician-patient relations in dermatology] |
|
| The plasticity of mRNA translation during cancer progression and therapy resistance |
|
| Postępy w opanowywaniu skórnych działań niepożądanych leków ukierunkowanych molekularnie = Advances in the management of cutaneous toxicities targeted therapies |
|
| Premier épisode d'infection urinaire fébrile de l'enfant:Enquête rétrospective dans un service de pédiatrie générale et actualisation des données de la littérature |
|
| The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network |
|
| The proof of concept that culturomics can be superior to metagenomics to study atypical stool samples |
|
| Radiotherapy as a risk factor for malignant melanoma after childhood skin hemangioma |
|
| Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. |
|
| RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors |
|
| Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering |
|
| Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8⁺ T lymphocyte emergence |
|
| Renal effects of immune checkpoint inhibitors |
|
| Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody |
|
| Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma |
|
| [Rothmund-Thomson syndrome with reduced DNA repair capacity] |
|
| Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease |
|
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma |
|
| Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer |
|
| Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma |
|
| Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination |
|
| Salt in stools is associated with obesity, gut halophilic microbiota and Akkermansia muciniphila depletion in humans |
|
| Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). |
|
| Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization |
|
| Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma |
|
| Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma |
|
| Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study |
|
| Seminal vesicle metastasis of cutaneous malignant melanoma: An unusual and challenging presentation |
|
| Sentinel lymph node biopsy in 33 non-melanoma skin cancers of the head and neck: A twelve-year experience with long-term follow-up |
|
| Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety |
|
| Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? |
|
| Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab |
|
| [Sezary syndrome with palmoplantar bullous lesions] |
|
| Side effects and toxicities of targeted therapies in stage IV melanoma |
|
| Small molecules and targeted therapies in distant metastatic disease. |
|
| Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies |
|
| Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. |
|
| Split face study on the cutaneous tensile effect of 2-dimethylaminoethanol (deanol) gel. |
|
| Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT) |
|
| Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? |
|
| Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare. |
|
| Sun exposure profile in the French population. Results of the EDIFICE Melanoma survey |
|
| Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma |
|
| Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials |
|
| Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. |
|
| Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines |
|
| Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer |
|
| Systemic Therapy Options for Patients With Unresectable Melanoma |
|
| [Systemic treatment of melanoma brain metastases]. |
|
| Targeted therapies for renal cell carcinoma: review of adverse event management strategies |
|
| Targeted therapy-induced radiation recall |
|
| Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner |
|
| Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib |
|
| Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy. |
|
| Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma. |
|
| [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma]. |
|
| Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases |
|
| Traitement du mélanome métastatique avec mutation de BRAF mélanome métastatique |
|
| Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. |
|
| [Treating metastatic melanoma: Risk management]. |
|
| Treatment algorithms in stage IV melanoma |
|
| Treponema species enrich the gut microbiota of traditional rural populations but are absent from urban individuals |
|
| [Trichothiodystrophies: anomalies of the repair and transcription of genes] |
|
| Tyrosine kinase inhibition and grey hair |
|
| Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. |
|
| Update on the role of ipilimumab in melanoma and first data on new combination therapies |
|
| Use of sorafenib in patients with hepatocellular or renal carcinoma |
|
| Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial |
|
| Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors |
|
| Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study |
|
| Virgibacillus senegalensis sp. nov., a new moderately halophilic bacterium isolated from human gut |
|
| Visceral lesions occurring during follow-up of melanoma patients: a true place for other diagnosis than melanoma metastasis |
|
| What is new in oncodermatology? |
|
| What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? |
|
| Who benefits most from adjuvant interferon treatment for melanoma? |
|
| [Xeroderma pigmentosum. What may be expected from biological studies?] |
|
| Ρarticularité cliniques et impacts thérapeutiques des effets indésirables immunο-induits chez les patients atteints d'un mélanοme de stade ΙV |
|
